Breast Cancer Research · 2009 · 154 citations · 43 references
MedicineMolecular BiologyOncologyCarcinogenesisEpigeneticsMolecular OncologyCancer EpigeneticsDna MethylationDna Methylation ProfilingDuctal Carcinoma In SituEpigenetic Biomarker DiscoveryEpigenetic BiomarkersAberrant Dna MethylationCpg Island Aberrant MethylationCpg Island MethylationCpg Island Methylation PatternsDna Methylation BiomarkersMethylation ArraysMethylation BiomarkersNeoplastic Progression
INTRODUCTION: Aberrant methylation of CpG islands is a hallmark of cancer and occurs at an early stage in breast tumorigenesis. However, its impact on tumor development is not fully determined, and its potential as a diagnostic biomarker remains to be validated. Methylation profiling of invasive breast carcinoma has been largely explored. Conversely, very little and sparse information is available on early-stage breast cancer. To gain insight into the epigenetic switches that may promote and/or contribute to the initial neoplastic events during breast carcinogenesis, we have analyzed the DNA methylation profile of ductal carcinoma in situ, a premalignant breast lesion with a great potential to progress toward invasive carcinoma. METHODS: We have utilized a comprehensive and sensitive array-based DNA mapping technique, the methylated-CpG island recovery assay, to profile the DNA methylation pattern in ductal carcinoma in situ. Differential methylation of CpG islands was compared genome-wide in tumor DNA versus normal DNA utilizing a statistical linear model in the LIMMA software package. RESULTS: Using this approach, we have identified 108 significant CpG islands that undergo aberrant DNA methylation in ductal carcinoma in situ and stage I breast tumors, with methylation frequencies greater than or comparable with those of more advanced invasive carcinoma (50% to 93%). A substantial fraction of these hypermethylated CpG islands (32% of the annotated CpG islands) is associated with several homeobox genes, such as the TLX1, HOXB13, and HNF1B genes. Fifty-three percent of the genes hypermethylated in early-stage breast cancer overlap with known Polycomb targets and include homeobox genes and other developmental transcription factors. CONCLUSIONS: We have identified a series of new potential methylation biomarkers that may help elucidate the underlying mechanisms of breast tumorigenesis. More specifically, our results are suggestive of a critical role of homeobox gene methylation in the insurgence and/or progression of breast cancer.
43
Polycomb complexes repress developmental regulators in murine embryonic stem cells
Laurie A. Boyer, Kathrin Plath, Julia Zeitlinger et al. · Nature · 2006 · 2.5K citations
AJCC Cancer Staging Manual. 6th ed
FL Greene, DL Page, Fleming Id et al. · 2002 · 2.3K citations
Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Tong Ihn Lee, Richard G. Jenner, Laurie A. Boyer et al. · Cell · 2006 · 2.3K citations · Full text
The Polycomb group protein EZH2 directly controls DNA methylation
Emmanuelle Viré, Carmen Brenner, Rachel Deplus et al. · Nature · 2005 · 2.2K citations